{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:27:26Z","timestamp":1791502046109,"version":"4.3.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T00:00:00Z","timestamp":1524182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS038377"],"award-info":[{"award-number":["NS038377"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS098006"],"award-info":[{"award-number":["NS098006"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS082205"],"award-info":[{"award-number":["NS082205"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Il-Yang Pharmaceutical Co.Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1093\/hmg\/ddy143","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T15:09:56Z","timestamp":1524150596000},"page":"2344-2356","source":"Crossref","is-referenced-by-count":78,"title":["The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model"],"prefix":"10.1093","volume":"27","author":[{"given":"Saebom","family":"Lee","sequence":"first","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjune","family":"Kim","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Joo","family":"Park","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Pil","family":"Yun","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hwan","family":"Kwon","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Central Research Institute, Il-Yang Pharmaceutical Co. Ltd., Yongin-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Soo","family":"Shin","sequence":"additional","affiliation":[{"name":"Central Research Institute, Il-Yang Pharmaceutical Co. Ltd., Yongin-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Jin","family":"Cho","sequence":"additional","affiliation":[{"name":"Central Research Institute, Il-Yang Pharmaceutical Co. Ltd., Yongin-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong Yeal","family":"Lee","sequence":"additional","affiliation":[{"name":"Central Research Institute, Il-Yang Pharmaceutical Co. Ltd., Yongin-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Soo","family":"Ju","sequence":"additional","affiliation":[{"name":"Central Research Institute, Il-Yang Pharmaceutical Co. Ltd., Yongin-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Yun","sequence":"additional","affiliation":[{"name":"Central Research Institute, Il-Yang Pharmaceutical Co. Ltd., Yongin-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonjoong Richard","family":"Kim","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ah","family":"Jung","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seulki","family":"Lee","sequence":"additional","affiliation":[{"name":"The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Neuraly, Inc., Germantown, MD 20876, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Seok","family":"Ko","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA"},{"name":"Neuraly, Inc., Germantown, MD 20876, USA"},{"name":"Diana Helis Henry Medical Research Foundation, New Orleans, LA 70130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"key\n\t\t\t\t20180618193551_ddy143-B1","first-page":"1744","article-title":"Diagnosis and treatment of Parkinson disease: molecules to medicine","volume":"116","author":"Savitt","year":"2006","journal-title":"J. Clin. Investig"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B2","first-page":"1044","article-title":"Parkinson's disease. First of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N. Engl. J. Med"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B3","first-page":"1130","article-title":"Parkinson's disease. Second of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N. Engl. J. Med"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B4","first-page":"819","article-title":"Molecular pathways of neurodegeneration in Parkinson's disease","volume":"302","author":"Dawson","year":"2003","journal-title":"Science"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B5","first-page":"643","article-title":"Oxidative and nitrosative stress in Parkinson's disease","volume":"1792","author":"Tsang","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B6","first-page":"240","article-title":"Oxidative stress and genetics in the pathogenesis of Parkinson's disease","volume":"7","author":"Zhang","year":"2000","journal-title":"Neurobiol. Dis"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B7","first-page":"326","article-title":"Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species","volume":"17","author":"Alvarez","year":"2004","journal-title":"Neurobiol. Dis"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B8","first-page":"201","article-title":"c-Abl in oxidative stress, aging and cancer","volume":"4","author":"Li","year":"2005","journal-title":"Cell Cycle"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B9","first-page":"445","article-title":"c-Abl in neurodegenerative disease","volume":"45","author":"Schlatterer","year":"2011","journal-title":"J. Mol. Neurosci"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B10","first-page":"157","article-title":"Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease","volume":"31","author":"Imam","year":"2011","journal-title":"J. Neurosci"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B11","first-page":"16691","article-title":"Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function","volume":"107","author":"Ko","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B12","first-page":"542","article-title":"c-Abl-p38alpha signaling plays an important role in MPTP-induced neuronal death","volume":"23","author":"Wu","year":"2016","journal-title":"Cell Death Differ"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B13","first-page":"2970","article-title":"Activation of tyrosine kinase c-Abl contributes to alpha-synuclein-induced neurodegeneration","volume":"126","author":"Brahmachari","year":"2016","journal-title":"J. Clin. Invest"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B14","first-page":"2858","article-title":"c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum. Mol. Genet"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B15","first-page":"254","article-title":"c-Abl Inhibitors enable insights into the pathophysiology and neuroprotection in Parkinson's disease","volume":"8","author":"Lindholm","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B16","first-page":"547","article-title":"The c-Abl inhibitor in Parkinson disease","volume":"38","author":"Zhou","year":"2017","journal-title":"Neurol. Sci"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B17","first-page":"4874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease","volume":"4","author":"Karuppagounder","year":"2015","journal-title":"Sci. Rep"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B18","first-page":"3315","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B19","first-page":"e65129","article-title":"Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model","volume":"8","author":"Imam","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B20","first-page":"503","article-title":"Nilotinib effects in Parkinson's disease and Dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J. Parkinsons Dis"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B21","first-page":"20051","article-title":"Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells","volume":"106","author":"Luk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B22","first-page":"57","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B23","first-page":"10154","article-title":"Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons","volume":"33","author":"Dryanovski","year":"2013","journal-title":"J. Neurosci"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B24","first-page":"2389","article-title":"TMEM175 deficiency impairs lysosomal and mitochondrial function and increases alpha-synuclein aggregation","volume":"114","author":"Jinn","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B25","first-page":"2107","article-title":"Fibril growth and seeding capacity play key roles in alpha-synuclein-mediated apoptotic cell death","volume":"22","author":"Mahul-Mellier","year":"2015","journal-title":"Cell Death Differ"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B26","first-page":"798","article-title":"GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B27","first-page":"949","article-title":"Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B28","article-title":"Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B29","first-page":"930","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B30","first-page":"1939","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B31","first-page":"2531","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B32","first-page":"4567","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B33","first-page":"1191","article-title":"Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors","volume":"99","author":"Kim","year":"2014","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B34","first-page":"1765","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B35","first-page":"1999","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters","volume":"23","author":"Davies","year":"2009","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B36","first-page":"1271","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis","volume":"13","author":"Soverini","year":"2012","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B37","first-page":"624","article-title":"Involvement of c-Abl kinase in microglial activation of NLRP3 inflammasome and impairment in autolysosomal system","volume":"12","author":"Lawana","year":"2017","journal-title":"J. Neuroimmune. Pharmacol"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B38","first-page":"17281","article-title":"Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress","volume":"276","author":"Kumar","year":"2001","journal-title":"J. Biol. Chem"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B39","first-page":"1249","article-title":"c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice","volume":"32","author":"Cancino","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B40","first-page":"eaaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Sci. Transl. Med"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B41","first-page":"2135","article-title":"Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates","volume":"9","author":"Volpicelli-Daley","year":"2014","journal-title":"Nat. Protocol"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B42","first-page":"11696","article-title":"Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration","volume":"112","author":"Stevens","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B43","first-page":"14524","article-title":"Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP","volume":"99","author":"Dauer","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"key\n\t\t\t\t20180618193551_ddy143-B44","first-page":"334","article-title":"The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat","volume":"22","author":"Lane","year":"2006","journal-title":"Neurobiol. Dis"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/27\/13\/2344\/25061234\/ddy143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:37:55Z","timestamp":1529350675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/27\/13\/2344\/4980307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":44,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2018,4,20]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddy143","relation":{},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,4,20]]}}}